| Not Yet Recruiting | Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) NCT07477769 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cuta NCT07535710 | Shanghai Jiao Tong University School of Medicine | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Thera NCT07213882 | Assistance Publique - Hôpitaux de Paris | EARLY_Phase 1 |
| Recruiting | Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance NCT07132567 | Kyowa Kirin Co., Ltd. | — |
| Active Not Recruiting | Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome NCT05944562 | Washington University School of Medicine | Phase 1 |
| Active Not Recruiting | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T- NCT05377827 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Registry for People With T-cell Lymphoma NCT05978141 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | Ritlecitinib in CTCL NCT05879458 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Recruiting | Extracorporeal Photopheresis in Sezary Syndrome NCT05157581 | Oleg E. Akilov, MD, PhD | — |
| Recruiting | Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma NCT04930653 | City of Hope Medical Center | Phase 2 |
| Unknown | Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association NCT05206045 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat NCT04955340 | 4SC AG | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome NCT04960618 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides NCT04676087 | Emory University | Phase 1 / Phase 2 |
| Terminated | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogam NCT04541017 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. NCT04904146 | Lund University Hospital | — |
| Completed | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Trea NCT04312841 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Recruiting | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome NCT04256018 | Stanford University | Phase 2 |
| Completed | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Ad NCT04185220 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides NCT03695471 | Mayo Clinic | Phase 2 |
| Completed | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancie NCT03905135 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas NCT03373305 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL NCT03602157 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients NCT03587844 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma NCT02341209 | Rochester General Hospital | Phase 2 |
| Active Not Recruiting | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractor NCT02978625 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripher NCT03011814 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrom NCT02953301 | 4SC AG | Phase 2 |
| Unknown | AEDV Registry of Primary Cutaneous Lymphoma NCT03646422 | Fundación Academia Española de Dermatología | — |
| Completed | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715 | Mayo Clinic | N/A |
| Terminated | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome NCT01625455 | Vanderbilt University Medical Center | Phase 4 |
| Completed | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level NCT01396070 | Youn Kim | Phase 2 |
| Completed | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma NCT01134341 | Acrotech Biopharma Inc. | Phase 1 |
| Completed | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma NCT00896493 | Stanford University | Phase 2 |
| Completed | Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cel NCT00748319 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) NCT00611208 | Angimmune LLC | Phase 2 |
| Completed | Effect of Denileukin Diftitox on Immune System in CTCL Patients NCT00254332 | University of Pittsburgh | — |
| Unknown | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome NCT00157274 | Latin American Cooperative Onco-Haematology Group - Peru | Phase 2 |
| Terminated | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome NCT00127881 | Emergent Product Development Seattle LLC | Phase 3 |
| Completed | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL NCT00178841 | Vanderbilt University | Phase 2 |
| Completed | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) NCT00091559 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research NCT00177268 | University of Pittsburgh | — |
| Completed | Immunization Against Tumor Cells in Sezary Syndrome NCT00099593 | University of Pittsburgh | Phase 2 |
| Completed | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome NCT00047060 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Completed | In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) NCT00177190 | University of Pittsburgh | — |
| Completed | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients NCT00051012 | Eisai Inc. | Phase 4 |
| Completed | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients NCT00050999 | Eisai Inc. | Phase 4 |